NEW YORK (GenomeWeb News) – Precision BioSciences has filed a fifth lawsuit against French company Cellectis alleging patent infringement.
The litigation filed in the US District Court for the Eastern District of North Carolina alleges infringement by Cellectis on US Patent No. 8,129,134, which pertains to Precision Bio's Directed Nuclease Editor genome engineering technology. Precision seeks monetary damages and a permanent injunction against Cellectis from making, using, selling, offering for sale, or importing the alleged infringing engineered meganucleases in the US.
The lawsuit is the latest in a patent fight between the two firms. In the past month, Precision Bio, headquartered in Research Triangle Park, NC, has sued Cellectis claiming infringement of US Patent No. 8,124,369, as well as US Patent Nos. 8,119,381 and 8,119,361.
In the fall, it sued Cellectis alleging infringement of US Patent No. 8,021,867. Cellectis also is suing Precision Bio, saying the company infringes on its US Patent No. 7,897,372.